A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
27/01/2021at 15:36

Ambu to raise USD 212m in new capital

While Ambu has had an extraordinary start to the year due to Covid-19, the Danish medtech firm now plans to raise a large amount of extra capital for further initiatives that can accelerate growth.
Photo: Ambu / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Ambu plans to raise DKK 1.3bn (USD 212m) in fresh capital through the private placement of new and existing shareholders in an accelerated bookbuilding process, which Ambu announced on Wednesday morning, on which occasion the medtech firm presented its fiscal report for Q1 of the staggered financial year 2020/20201, which in many ways turned out even better than analysts expected.

This move is a way of strengthening Ambu's capital base, which can provide the firm with more strategic and operational flexibility, writes the company in the announcement.

"Growth of the single-use endoscopy market has accelerated on the back of an increased awareness of contamination levels and technological advances, and the COVID-19 pandemic has further increased the receptiveness to single-use endoscopy," writes Ambu in the statement.

Ambu aspires to become the most innovative player on the market for single-use endoscopies, and in order to reach this goal and attain more flexibility the firm sees it as necessary to raise DKK 1.3bn.

The proceeds will go towards paying back debts, according to the company announcement.

Financial institutions Danske Bank, J.P. Morgan AG and Nordea Danmark are acting as joint global coordinators and joint bookrunners for this offering, according to Ambu.

Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.

Germany to start registering single-use scopes – Ambu to take advantage 

WS Audiology plans to beat competition by way of younger target group – launches hearing aid designed like Apple earbuds 

Coloplast CEO urged to take action: Release the billions! 

Ambu lands new single-use endoscope contract with US GPO 

 

Related articles:

  • Photo: Ambu / PR

    Germany to start registering single-use scopes – Ambu to take advantage

    For subscribers

  • Photo: WS Audiology / PR

    WS Audiology plans to beat competition by way of younger target group – launches hearing aid designed like Apple earbuds

    For subscribers

  • Coloplast CEO Kristian Villumsen | Photo: Stine Bidstrup/ERH

    Coloplast CEO urged to take action: Release the billions!

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Commercial Director

  • Application Manager

  • Head of International Sales

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Head of Regulatory Affairs Danmark

  • Principal Laboratory Technologist

  • Clinical Operational Associate

See all jobs

Jobs

  • Commercial Director

  • Application Manager

  • Head of International Sales

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Head of Regulatory Affairs Danmark

  • Principal Laboratory Technologist

  • Clinical Operational Associate

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge